NGEN — Nervgen Pharma Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$129.85m
- CA$115.28m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.36 | -9.77 | -11.2 | -12.7 | -20.7 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -0.006 | 1.43 | 3.43 | 3.98 | 0.708 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.304 | 0.207 | 1.41 | 0.43 | 2.11 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -1.04 | -8.09 | -6.31 | -8.27 | -17.8 |
Capital Expenditures | -0.127 | 0 | -0.003 | -0.045 | -0.021 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Cash from Investing Activities | -0.127 | 0 | -0.003 | -0.045 | -0.021 |
Financing Cash Flow Items | — | -0.901 | -1.17 | -1.67 | -0.129 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 3.59 | 9.84 | 7.85 | 19.6 | 22.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.47 | 1.63 | 1.49 | 11.3 | 5.52 |